DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2007-D-0369]

# Product-Specific Bioequivalence Recommendations; Draft and Revised Draft Guidances for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific bioequivalence (BE) recommendations. The recommendations provide product-specific guidance on the design of BE studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry entitled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site. The BE recommendations identified in this notice were developed using the process described in that guidance.

DATES: Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comments on these draft and revised draft guidances before it begins work on the final versions of the guidances, submit either electronic or written comments on the draft and revised draft product-specific BE recommendations listed in this notice by [INSERT DATE 60 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL

REGISTER].

ADDRESSES: Submit written requests for single copies of the individual BE guidances to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance recommendations.

Submit electronic comments on the draft product-specific BE recommendations to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Xiaoqiu Tang, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, rm. 4730, Silver Spring, MD 20993-0002, 301-796-5850.

SUPPLEMENTARY INFORMATION:

## I. Background

In the Federal Register of June 11, 2010 (75 FR 33311), FDA announced the availability of a guidance for industry entitled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific BE recommendations available to the public on FDA's Web site at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.

As described in that guidance, FDA adopted this process as a means to develop and disseminate product-specific BE recommendations and provide a meaningful opportunity for the

public to consider and comment on those recommendations. Under that process, draft recommendations are posted on FDA's Web site and announced periodically in the Federal Register. The public is encouraged to submit comments on those recommendations within 60 days of their announcement in the Federal Register. FDA considers any comments received and either publishes final recommendations or publishes revised draft recommendations for comment. Recommendations were last announced in the Federal Register on March 9, 2015 (80 FR 12502). This notice announces draft product-specific recommendations, either new or revised, that are posted on FDA's Web site.

II. Drug Products for Which New Draft Product-Specific BE Recommendations are Available

FDA is announcing the availability of a new draft guidance for industry on product-specific BE recommendations for drug products containing the following active ingredients:

Table 1. New Draft Product-Specific BE Recommendations for Drug Products

| |
|---|
| Abacavir sulfate; Dolutegravir sodium; Lamivudine |
| Afatinib dimaleate |
| Alendronate sodium |
| Aspirin |
| Azelastine hydrochloride; Fluticasone propionate |
| Budesonide; Formoterol fumarate dihydrate |
| Calcium carbonate; Famotidine; Magnesium hydroxide |
| Canagliflozin; Metformin hydrochloride |
| Cyclophosphamide |
| Cyproheptadine hydrochloride |
| Dabrafenib mesylate |
| Dapagliflozin propanediol |
| Dexbrompheniramine maleate and Pseudoephedrine sulfate |
| Dolutegravir sodium |
| Donepezil hydrochloride; Memantine hydrochloride |
| Doxycycline hyclate |
| Droxidopa |
| Eliglustat tartrate |
| Empagliflozin |
| Emtricitabine; Tenofovir disoproxil fumarate |
| Enzalutamide |
| Fentanyl |
| Indomethacin |
| Lanthanum carbonate |
| Levalbuterol tartrate |
| Levomilnacipran hydrochloride |
| Macitentan |

Table 1. New Draft Product-Specific BE Recommendations for Drug Products

| |
|---|
| Methazolamide |
| Miglitol |
| Naloxegol oxalate |
| Naproxen sodium |
| Nitroglycerin |
| Omeprazole; Sodium bicarbonate |
| Oxybutynin (multiple reference listed drugs and dosage forms) |
| Oxycodone hydrochloride |
| Primaquine phosphate |
| Sildenafil citrate |
| Simeprevir sodium |
| Sofosbuvir |
| Tolcapone |
| Vemurafenib |
| Vismodegib |
| Vortioxetine hydrobromide |

## III. Drug Products for Which Revised Draft Product-Specific BE Recommendations are Available

FDA is announcing the availability of a revised draft guidance for industry on product-specific BE recommendations for drug products containing the following active ingredients:

| Table 2. Revised Draft Product-Specific BE Recommendations for Drug ProductsCholestyramine |
|---|
| Doxycycline hyclate |
| Prasugrel hydrochloride |
| Tiagabine hydrochloride |

For a complete history of previously published Federal Register notices related to product-specific BE recommendations, go to http://www.regulations.gov and enter Docket No. FDA-2007-D-0369.

These draft and revised draft guidances are being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). These guidances represent the Agency's current thinking on product-specific design of BE studies to support ANDAs. They do not establish any rights for anyone and are not binding on FDA or the public. You may use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

## IV. Comments

Interested persons may submit either electronic comments on any of the specific BE recommendations posted on FDA's Web site to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. The guidances, notices, and received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

## V. Electronic Access

Persons with access to the Internet may obtain the document at either http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov.

Dated: June 24, 2015.

Leslie Kux,

Associate Commissioner for Policy.

4164-01-P

[FR Doc. 2015-16013 Filed: 6/29/2015 08:45 am; Publication Date: 6/30/2015]